Price cut sways NICE on Zytiga
May 16, 2012Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer
NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance. In its final guidance, the watchdog is recommending …
Open Health appoints new digital designer
May 16, 2012Business Services, Medical Communications, Sales and Marketing Open Health
Leo Jacobs has been appointed by Open Health as a digital designer to sit within its OPEN Source team. The …
Merck KGaA sets out savings target as staff threaten to strike
May 15, 2012Research and Development, Sales and Marketing Merck KGaA, R&D, Serono, cuts
Merck KGaA has outlined its plan to make €300 million in savings from its Serono drugs unit, with over half …
CoreLab Partners collaborates at industry conferences worldwide
May 15, 2012Research and Development
Princeton, NJ May 15, 2012 – CoreLab Partners, Inc, a leading independent core lab providing centralized cardiac safety services and …
Genentech taken to task over Avastin production
May 15, 2012Manufacturing and Production Genentech, Phil Taylor, avastin, manufacturing
FDA inspections of a manufacturing facility for Roche/Genentech’s cancer drug Avastin (bevacizumab) uncovered a number of deficiencies which could increase …
ABPI launches new NHS partnership guide
May 15, 2012Medical Communications, Sales and Marketing ABPI, COPD, NHS, code
The Association of the British Pharmaceutical Industry has launched a new guide to explain how pharma and the NHS can …
GlaxoSmithKline to acquire Cellzome for £61 million
May 15, 2012Research and Development, Sales and Marketing Cellzome, Domantis, GSK, R&D
GlaxoSmithKline will expand its platform technology capability with the acquisition of a chemical proteomics company. GSK will acquire those shares …
Synthetic Biologics appoints Carol Reed
May 15, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Carol Reed, Synthetic
Synthetic Biologics has appointed Carol Reed as senior vice president of Clinical & Regulatory Affairs. In this position Reed will …
Gilenya to stay on US market – but with new safety warnings
May 15, 2012Sales and Marketing EMA, FDA, Novartis, PML, gilenya
The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …
Scottish watchdog rejects Yervoy
May 14, 2012Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma
The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy. The SMC said that Yervoy (ipilimumab), which has …
New Quad HIV pill on track for FDA approval
May 14, 2012Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad
Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group. The US regulator is …
Obesity drugs vie for approval as FDA panel backs lorcaserin
May 14, 2012Research and Development, Sales and Marketing Arena, Eisai, FDA, Qnexa, lorcaserin, obesity
An FDA panel has recommended Arena’s obesity drug lorcaserin, setting up a showdown with Vivus’ Qnexa. Qnexa was recommended by an FDA panel …
BASF buys Equateq to tap into growing health ingredient business
May 11, 2012Manufacturing and Production BASF, Equateq, Phil Taylor, omega-3
BASF has said it intends to buy Equateq, a UK-based specialist in lipid ingredients that represent a ‘global growing market’, …
Outsourcing on the up, but contract manufacturing still under pressure
May 11, 2012Manufacturing and Production CMO, Jim Millar, PharmaSource, Phil Taylor, outsourcing
The pharmaceutical contract services sector experienced something for a recovery in 2011 after a lean couple of years, although the …
Code of Practice update to reflect legal changes
May 11, 2012Medical Communications ABPI, Code of Practice, MHRA, PMCPA, patient organisations
The UK pharma industry’s Code of Practice is set to be updated to bring it into line with changes in …
NICE changes its mind on Botox
May 11, 2012Sales and Marketing Allergan, Botox, NHS, NICE
NICE is now recommending Allergan’s Botox for chronic migraines, reversing its previous decision. The watchdog said in final draft guidance …
Gamification and online communities – what can pharma do?
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Facebook, Gamification, Syrum, digital marketing
Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This new …
ABPI appoints new Innovation Board Chair
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Neil Weir, Whitehead
The senior vice president of discovery at UCB, Neil Weir, has been appointed as the next Chair of the ABPI …
Teva appoints new president and chief executive
May 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Jeremy Levin, Teva
Ex-BMS head Dr Jeremy Levin has been appointed president and chief executive of Teva. Prior to joining Teva, Levin, who …
Patheon starts winding down Swindon operations
May 10, 2012Manufacturing and Production CMO, Patheon, Swindon, manufacturing
North American contract manufacturer Patheon is winding down some operations at its facility in Swindon, UK, with the aim of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
